...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: USA ZHCLF investors

RVXOT:

"From Zenith Capital Corp. MD&A:

As at July 31, 2022, we hold all 75,202,620 royalty preferred shares of Resverlogix. We, as the sole holder of the royalty preferred shares of Resverlogix, are entitled to dividends in the amount of 6-12% of Resverlogix’s Net Revenue, if any"

Presumably, this would only apply to "ZHCLF" shares trading on the OTC market. It would not apply to Zenith shares acquired directly from Zenith post SPINCO 2013.

Would it be a problem distinguishing between the two sets of Zenith shares when it comes to issuing dividends? 

 

Koo

 

 

Share
New Message
Please login to post a reply